Review of Genetic Variants of Butyrylcholinesterase and Their Potential Impact on Human Health

Bharmatisna Anggaharsya Nugraha

1Department of Neurology, Faculty of Medicine, Sriwijaya University, Palembang, Indonesia

ARTICLE INFO

Keywords:
Genetic Variant
Butyrylcholinesterase
Neuromuscular Junction

Corresponding author:
Bharmatisna Anggaharsya Nugraha

E-mail address:
dr.bharmatisna@yahoo.co.id

The author has reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/OAIJMR.v1i6.575

ABSTRACT

Butyrylcholinesterase (BChE) is an enzyme found in plasma and many other parts of the body. It is enzyme that hydrolyses drugs containing ester bonds such as drugs acting at the neuromuscular junction (succinylcholine) and local anaesthetics (procaine). Examination of the gene for mutations or polymorphisms causing the observed biochemical phenotypes has isolated those responsible for all the most widely known variants. The molecular bases of several genetic variants of BChE have been reported, such as the Atypical variant, fluoride-resistant variant, silent variant, K variant, J variant and C5 variant. In general, BChE polymorphisms have been shown to produce enzymes with varying levels of catalytic activity. Genetic variants of human butyrylcholinesterase were one of the first examples in the new field of pharmacogenetics when it was recognized that abnormal response to the succinylcholine was due to a mutated enzyme with low binding affinity. Beside that, variant of BChE has potential impact for Alzheimer disease pathology.

Introduction

Butyrylcholinesterase (BChE) is an enzyme found in plasma and many other parts of the body. Butyrylcholinesterase is a tetrameric glycoprotein with a molecular mass of 342 kDa. It is synthesized primarily in the liver and distributed in the intestinal mucosa, blood plasma and the white matter of the central nervous system. It consists of four identical subunits, each of which has an active catalytic site.

Butyrylcholinesterase (BChE) still occasionally called pseudo-cholinesterase and acetylcholinesterase (AChE) called true cholinesterase. Both are enzymes that hydrolyse choline esters. Although both enzymes share very close sequence homology, they can be distinguished by substrate preference, inhibitor specificity and antibody recognition. Butyrylcholinesterase is involved in the metabolism of drugs. It is enzyme that hydrolyses drugs containing ester bonds such as drugs acting at the neuromuscular junction such as succinylcholine and local anaesthetics such as procaine. It is also a biological scavenger for organophosphorus and carbamate compounds used as pesticides.1

Butyrylcholinesterase (BChE) is encoded by a single gene locus. The gene is located on chromosome 3q26.1-q.26.2. It is minimally 73 kilobases long with four exons separated by three introns. The gene encodes a transcript of 2400bp in size and a protein of 574 amino acids. The gene product is the Butyrylcholinesterase (BChE) subunit, four of which are needed to make the active enzyme. Exon 2 is large and codes for 83% of the subunit, including the active site at amino acid 198.
Examination of the gene for mutations or polymorphisms causing the observed biochemical phenotypes has isolated those responsible for all the most widely known variants. To date, more than 100 polymorphisms have been identified, however few have been studied fully. In general, Butyrylcholinesterase (BChE) polymorphisms have been shown to produce enzymes with varying levels of catalytic activity. The molecular bases of several genetic variants of BChE have been reported, such as the Atypical gene, fluoride-resistant gene, silent gene, K variant, J variant and C5 variant. In addition there are a number of additional BChE polymorphisms which result in a protein with no enzymatic activity. Enzymes with activity below 10% of the wild type enzyme are called “silent” variants.  

**Atypical Butyrylcholinesterase**

Genetic variants of human butyrylcholinesterase were one of the first examples in the new field of pharmacogenetics when it was recognized that abnormal response to the muscle relaxant succinylcholine was due to a mutated enzyme with low binding affinity. Neuromuscular block induced by succinylcholine or mivacurium can be significantly prolonged if the patient has an abnormal genetic variant of butyrylcholinesterase.

The trait was called succinylcholine apnea and was shown to be hereditary. A standard dose of succinylcholine paralyzed most individuals for 3–5 min, but people with “atypical” butyrylcholinesterase could not breathe for 2 h. The paralyzed person was awake and could see and hear, but could not breathe without assisted ventilation. Werner Kalow devised a simple inhibition assay, called the dibucaine number, to phenotype blood samples. This assay has been used worldwide on over 100,000 human samples.

Analysis of butyrylcholinesterase involves the determination of both enzyme activity and biochemical phenotypes. Phenotype is determined by the use of specific enzyme inhibitors (such as dibucaine or fluoride) that produce phenotype-specific patterns of dibucaine or fluoride numbers. Molecular genetic analyses can determine the true genotypes. The dibucaine number phenotyping method has proven to be 100% reliable in identifying the atypical variant as well as carriers of the atypical variant when comparing phenotype to DNA sequencing results. The atypical variant was identified in 1989 as a single amino acid substitution that changes aspartic acid 70 to glycine.  

Among the variants of butyrylcholinesterase is a dibucaine-resistant variant, a result of a point mutation in exon 2 (nt 209A → G), which is manifested by an amino acid change Asp70→Gly (D70G mutation). About 1 out of 2500 Americans is homozygous for the D70G mutation. Dibucaine inhibits normal butyrylcholinesterase to a far greater extent than the abnormal enzyme. The dibucaine number indicates the percentage inhibition of butyrylcholinesterase in the presence of dibucaine.

In the case of the usual butyrylcholinesterase genotype (E1uE1u), the dibucaine number is 70 or higher, while in individuals homozygous for the
atypical gene (E1aE1a) (frequency in general population of 1 in 3,500), the dibucaine number is less than 30. In individuals with the heterozygous atypical variant (E1uE1a) (frequency in general population of 1 in 480), the dibucaine number is in the range of 40 to 60. In individuals with the homozygous atypical genotype (E1aE1a), the neuromuscular block induced by succinylcholine or mivacurium is prolonged to 4 to 8 hours, and in individuals with the heterozygous atypical genotype (E1uE1a), the period of neuromuscular block induced by succinylcholine or mivacurium is about 1.5 to 2 times that seen in individuals with the usual genotype (E1uE1u).

People who are homozygous for atypical (D70G) or silent butyrylcholinesterase are 100% certain to experience prolonged apnea in response to standard doses of succinylcholine and mivacurium. It is hypothesized that they will also respond abnormally to cocaine, but this has not been demonstrated. The longest period of apnea after the administration of succinylcholine was found in patients homozygous for the silent gene (E1sE1s). In those patients, train-of-four stimulation will help in detecting the development of phase II block. The decision whether to attempt antagonism of a phase II block has always been controversial. However, if the train-of-four ratio is less than 0.4, administration of edrophonium or neostigmine should result in prompt antagonism. The alternative is to keep the patient adequately sedated and maintain artificial ventilation until the train-of-four ratio has recovered to 0.9 or more.

Fluoride resistant butyrylcholinesterase

Fluoride resistant butyrylcholinesterase variants have also been described. In the case of the fluoride-resistant gene, two amino acid substitutions are possible, namely, methionine for threonine at position 243 and valine for glycine at position 390. The fluoride number indicates the percentage inhibition of butyrylcholinesterase in the presence of fluoride. In case of the usual butyrylcholinesterase genotype (E1uE1u), the fluoride number is 60, while in individuals with the homozygous atypical genotype (E1fE1f), the fluoride number is 36. The fluoride-resistant gene was found in 2.7 % of patients with prolonged apnea after administration of succinylcholine.

Individuals with homozygous fluoride-resistant genotype exhibit mild to moderate prolongation of succinylcholine-induced paralysis. The heterozygous fluoride-resistant genotype usually produces clinically insignificant prolongation of succinylcholine block, unless accompanied by a second abnormal allele or by a coexisting acquired cause of butyrylcholinesterase deficiency.

Silent Butyrylcholinesterase

People with silent butyrylcholinesterase have a prolonged response to succinylcholine. The silent variant has 0–10% of normal butyrylcholinesterase activity. About 1 in 100,000 Americans and Europeans is homozygous for silent butyrylcholinesterase, though communities such as the Vysya of India and the Eskimos of Alaska have frequencies as high as 1 out of 24 for homozygous silent butyrylcholinesterase. No single mutation is responsible for the silent variant. The silent butyrylcholinesterase variant includes many types of mutations. Some silent variants have a frameshift mutation, others have an amino acid substitution that destabilizes the enzyme, and others have an insertion.

K-variant Butyrylcholinesterase

There are also some so-called quantitative cholinesterase variants of butyrylcholinesterase (K, H, and J type). The K-variant is the most common one, with an allele frequency of 13%, and it results in a 30% decrease in activity due to the reduction of circulating active enzyme molecules. AG → A base change at position 1615 causes an amino acid alteration Ala539 → Thr.

The “K-variant,” is found so frequently that it can be classified as a polymorphism. The K variant
(A539T), named in honor of Werner Kalow, is found in homozygous form in 1 out of 63 Americans and is carried by 1 out of 4.9

The K-variant causes a 33% reduction in the amount of butyrylcholinesterase circulating in plasma. The catalytic activity per molecule of butyrylcholinesterase is unaffected by the K-variant mutation, only the quantity of enzyme is reduced.10 It is hypothesized that the K-variant mutation is linked to a mutation in the promoter or enhancer, but this has not yet been proven. A single amino acid substitution, A539T, is found in the butyrylcholinesterase protein of the K variant. Multiple mutations are common. The atypical mutation is linked to the K-variant mutation so that almost all people who have the atypical mutation also have the K-variant mutation on the same allele.9

**J-variant butyrylcholinesterase**

The J-variant of human serum butyrylcholinesterase (BChE) causes both an approximately two-thirds reduction of circulating enzyme molecules and a corresponding decrease in the level of BChE activity present in serum. Since the level of serum BChE activity and the duration of succinylcholine apnea are inversely correlated, this marked decrease in activity makes individuals with the J-variant more susceptible than usual subjects to prolonged apnea from succinylcholine.

DNA amplification by PCR, followed by direct sequencing of the amplified DNA, led to the finding that the J-variant phenotype of human serum BChE was associated with two DNA point mutations in the coding region. One of these was the mutation previously identified with the K-variant phenotype (GCA-*ACA; Ala539--Thr). The other was an adenine-to-thymine transversion at nucleotide 1490, which changed amino acid 497 from glutamic acid to valine (GAA-JGTA; Glu497-0Val). This latter point mutation was named the J-variant mutation (formal name BCHE*497V). The J-variant mutation has not been identified without the K-variant mutation. The J-variant mutation created an Rsal-enzyme RFLP.11

**C5-variant Butyrylcholinesterase**

Although most genetic variants of serum butyrylcholinesterase are associated with decreased activity, some rare variants are associated with increased enzyme activity (2 to 3 times normal). These variants have normal dibucaine and fluoride numbers, and the enhanced activity has been attributed to either an increased number of enzyme molecules or increased activity per active site. One of these is C5-variant BChE.

It has been suggested, but not proven, that the unknown protein on chromosome 2 that associates with butyrylcholinesterase to make the C5 variant is lamellipodin. Mass spectrometry has provided strong evidence that the butyrylcholinesterase tetramer has proline-rich fragments within its tetramerization domain and these proline-rich fragments are derived from multiple proteins including lamellipodin.12 The gene for lamellipodin is located on chromosome 2q33, at the site of the unknown protein in the C5 variant. It is hypothesized that incompletely processed lamellipodin protein may explain the C5 variant of butyrylcholinesterase.

The C5 variant has an extra, slow-moving band of BChE activity on native polyacrylamide gel electrophoresis. This band is about 60 kDa larger than wild-type BChE. Umbilical cord BChE in 100% of newborn babies has a C5-like band. The C5 phenotype has a frequency of about 10% in Caucasians. Individuals phenotyped as C5 have 30% higher plasma BChE activity on average, but activity can range up to 200% higher than the majority of individuals. The C5 phenotype is associated with low body weight and a shorter duration of action of the muscle relaxant succinylcholine.13

**Potential Impact Variants of Butyrylcholinesterase on Human Health**

Genetic variants of human butyrylcholinesterase were one of the first examples in the new field of
pharmacogenetics when it was recognized that abnormal response to the muscle relaxant succinylcholine was due to a mutated enzyme with low binding affinity.3 Neurmuscular block induced by succinylcholine or mivacurium can be significantly prolonged if the patient has an abnormal genetic variant of butyrylcholinesterase.

People who are homozygous for atypical (D70G) or silent butyrylcholinesterase are 100% certain to experience prolonged apnea in response to standard doses of succinylcholine and mivacurium. It is hypothesized that they will also respond abnormally to cocaine, but this has not been demonstrated.6 Studies on butyrylcholinesterase knockout mice show that butyrylcholinesterase deficiency is associated with adverse effects to the Alzheimer's disease drugs huperzine A and donepezil.14 The mouse studies suggest that butyrylcholinesterase-deficient humans will not tolerate these acetylcholinesterase inhibitor drugs. Butyrylcholinesterase deficiency in humans is expected to increase susceptibility to the toxic effects of organophosphorus pesticides and nerve agents, but this has not been proven.

The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease. The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate β-amyloid (Aβ) fibril formation. This variant has neuroprotective characteristics caused by sustained acetylcholine levels and elevated Alzheimer disease risk due to inefficient interference with amyloidogenic processes.15

References

shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme. Journal of Neurochemistry, 74, 869–877


14. Duysen, E. G, Li, B, Darvesh, S, & Lockridge, O. 2007. Sensitivity of butyrylcholinesterase knockout mice to huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer’s disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology, 233, 60–69